VCAM
STAB

Van Cleef Asset Management’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Van Cleef Asset Management’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-500
Closed -$5K – 100
2014
Q2 		$5K Sell
500
-500
-50% -$5.84K ﹤0.01% 100
2014
Q1 		$14K Hold
1,000
– – 0.01% 95
2013
Q4 		$23K Hold
1,000
– – 0.01% 96
2013
Q3 		$31K Hold
1,000
– – 0.02% 93
2013
Q2 		$32K Buy
+1,000
New +$34.4K 0.02% 92

Other funds holding STAB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Van Cleef Asset Management's STAB Position: Q3 2014 in Review

Van Cleef Asset Management sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q3 2014, closing a stake of 500 shares — an estimated $5K sold.

Van Cleef Asset Management first reported a position in STAB in Q2 2013 and held it in 5 quarters. The position peaked at $32K in Q2 2013. 25 funds tracked by Wall St. Rank hold STAB as of Q3 2014.

  • Van Cleef Asset Management reported no remaining Statera Biopharma, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Van Cleef Asset Management sold 500 Statera Biopharma, Inc. Common Stock shares in Q3 2014, an estimated $5K.
  • Van Cleef Asset Management first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
  • Van Cleef Asset Management's Statera Biopharma, Inc. Common Stock position peaked at $32K in Q2 2013.
  • 25 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q3 2014.

Based on Van Cleef Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.